TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04960072: A Clinical Safety and Efficacy Study of Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With r/r Gastrointestinal Tumors

Sponsor: Shanghai Juncell Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT04960072 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04960072 Rescue Dossier →